Investigating how DYNLL1 affects DNA repair mechanisms in cancer cells
Official title: Project 1: Role of DYNLL1 in the 53BP1 Axis of HDR Regulation
Funded at University of Texas Hlth Science Center · NIH-10847788 · Data updated 2026-11-12
This study is looking at a protein called DYNLL1 to see how it helps our cells fix DNA damage, which is important for preventing cancer, and the findings could lead to new treatments for patients with certain types of cancer.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $634,883 |
| NIH project number | 1P01CA275717-01A1 |
| Project ID | NIH-10847788 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with breast or ovarian cancers, particularly those with BRCA1 mutations or other DNA repair pathway deficiencies.
✕Less likely to help
Patients with cancers unrelated to DNA repair mechanisms or those without genetic predispositions to such conditions may not benefit from this research.
What this research studies
This research explores the role of a protein called DYNLL1 in the regulation of DNA repair processes, specifically focusing on how it influences the choice between two pathways: homology-directed repair (HDR) and non-homologous end joining (NHEJ). By understanding how DYNLL1 interacts with other proteins involved in DNA repair, the research aims to uncover mechanisms that could lead to genomic instability and cancer development. The study will involve biochemical analyses and cellular experiments to assess the impact of DYNLL1 on DNA repair efficiency and cancer cell behavior. Patients may benefit from insights gained that could inform new therapeutic strategies for cancers associated with DNA repair deficiencies.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with cancers linked to DNA repair deficiencies, such as those with BRCA1 mutations.
How similar studies have gone: Other research has shown promising results in targeting DNA repair pathways in cancer treatment, indicating that this approach could lead to significant advancements.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Chowdhury, Dipanjan — University of Texas Hlth Science Center
- Study coordinator: Chowdhury, Dipanjan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.